Date:- 8 November, 2017
Tag:- IMMUNOSCORE® IC in NSCLC IMMUNOSCORE® in Colon Cancer
- HalioDx immune scoring solutions results presented by our biopharma partners at SITC 2017
- Halioseek® PD-L1/CD8 potential to improve selection of NSCLC[1] patients eligible to ICI[2]
- Meet HalioDx team at booth #512 to discuss abstracts content, discover HalioDx products and services
HalioDx SAS, an immuno-oncology diagnostic company, announced its participation at the SITC 2017 Annual Meeting with several posters presented by its collaborators and partners.
HalioDx will also present a poster on its Halioseek® PD-L1/CD8[3] assay which is now CE-IVD in Europe since October (See press release on Halioseek®CE-IVD launch).
HalioDx team will showcase its diagnostic products including Immunoscore® Colon and clinical research services on booth #512 and will be pleased to discuss with attendees during the SITC conference.
Vincent FERT, CEO of HalioDx comments: “SITC 2017 meeting is a unique opportunity for HalioDx to showcase the value of our Clinical Research portfolio through data presented by our biopharmaceutical partners, and to update attendees on our progresses toward establishing our immune scoring solutions as standards in immunotherapies clinical development.”
Poster presentations by our partners:
‘Antitumor immunity in patients with locally advanced soft tissue sarcoma treated with hafnium oxide nanoparticles and radiation therapy’
Poster Session: Oncolytic Viruses and Intratumoral Therapies
Poster Board #412
Session Time: Saturday, November 11, 2017 – 12:30 to 2 p.m. and 6:30 to 8 p.m.
Presenter: Sebastien Paris, Nanobiotix, Paris, France
‘LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the majority of patients with advanced metastatic tumors: Results from an ongoing study’
Poster Session: Clinical Trials (In Progress)
Poster Board #250
Session Time: Saturday, November 11, 2017 – 12:30 to 2 p.m. and 6:30 to 8 p.m.
Presenter: Aurelien Marabelle, Gustave Roussy, Villejuif, France
Poster presentation by HalioDx:
‘Halioseek®, a dual CD8 and PD-L1 IVD assay to improve NSCLC patients stratification’
Poster Session: Biomarkers and Immune Monitoring
Poster Board #70
Session Time: Saturday, November 11, 2017 – 12:30 to 2 p.m. and 6:30 to 8 p.m.
Presenter: Jacques Fieschi, HalioDx, Marseille, France
[1]Non-Small Cell Lung Cancer.
[2]Immune Checkpoint Inhibitors.
[3]For Research Use Only in USA. Not for Use in Diagnostic Procedures.